Results 191 to 200 of about 41,535 (224)

Association Between Discharge Medications and Oncologic Post-Embolization-Syndrome-Related Outcomes. [PDF]

Cancer Med
Li H, Moon J, Sim N, Horný M, Lima N, Konstantinidis M, Iyer D, Benenati S, Gichoya J, Newsome J, Bercu Z.   +10 more
europepmc   +1 more source

Atezolizumab plus Bevacizumab with Transcatheter Arterial Chemoembolization (Sandwich Strategy) versus Atezolizumab plus Bevacizumab Alone in Hepatocellular Carcinoma: A Multicenter Retrospective Study. [PDF]

Liver Cancer
Hashimoto K, Kawaoka T, Emori T, Tanaka A, Shirane Y, Miura R, Fujii Y, Nakahara H, Yamaoka K, Uchikawa S, Fujino H, Ono A, Murakami E, Miki D, Hayes CN, Hiramatsu A, Amioka K, Nonaka M, Aisaka Y, Morio K, Moriya T, Teraoka Y, Kono H, Suehiro Y, Masaki K, Ohya K, Takaki S, Mori N, Tsuji K, Kosaka Y, Nakahara T, Aikata H, Tsuge M, Oka S.   +33 more
europepmc   +1 more source

Retrospective analysis of transarterial chemoembolization or hepatic arterial infusion chemotherapy combined with lenvatinib with or without PD-1 inhibitor as first-line therapy for unresectable hepatocellular carcinoma with high tumor burden: a propensity score-matched study. [PDF]

Front Immunol
Li Z, Wu H, Xu R, Chang X, Wang S, Sun P.   +5 more
europepmc   +1 more source

Comparative effectiveness of adjuvant treatment for hepatocellular carcinoma with high risk of recurrence: A systematic review and network meta-analysis. [PDF]

PLoS One
Peng Z, Shen L, Wang Y, Chen B, Zhu Z, He C, Huang H.   +6 more
europepmc   +1 more source

Construction of a Prognostic Model Based on Insulin Resistance-Related Genes to Predict TACE Response and Identification of PD-98059 as a Potential Therapeutic Agent. [PDF]

J Hepatocell Carcinoma
Wang W, Chen K, Fan C, Sun L, Tang H, Ding W, Sun F, Wang W.   +7 more
europepmc   +1 more source

Immediate-Onset Acute Pancreatitis During Transarterial Chemoembolization: A Case Report. [PDF]

Cureus
Shen Y, Deng X, Chen Y, Lei J.
europepmc   +1 more source

Clinical efficacy of hepatic arterial infusion chemotherapy combined with transhepatic arterial embolization plus lenvatinib and tislelizumab or transarterial chemoembolization combined with lenvatinib plus tislelizumab in the treatment of advanced hepatocellular carcinoma. [PDF]

Front Oncol
Peng Z, Wang Y, Chen B, Zhu Z, He C, Wei Y, Huang H.   +6 more
europepmc   +1 more source

Prone transradial approach for radiofrequency ablation of hepatocellular carcinoma in the caudate lobe following TACE: a technical case report. [PDF]

Acta Radiol Open
Sato R, Asahara K, Saiga A, Aramaki T.
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Chemoembolization for hepatocellular carcinoma

Gastroenterology, 2004
Curative therapies for hepatocellular carcinoma (HCC), such as resection, liver transplantation, and percutaneous ablation, can be applied in selected patients with early tumors; this includes approximately 30%-40% of all cases. More advanced stages require local or systemic therapies.
Jordi, Bruix, Margarita, Sala, Josep M, Llovet   +2 more
openaire   +2 more sources

Hepatic artery chemoembolization

Seminars in Oncology, 2002
Chemoembolization is a technique that can deliver high concentrations of therapeutic agents directly to the liver for prolonged periods. Considerable experience has been gained in the treatment of hepatocellular carcinoma, where it appears to be a safe procedure that provides survival advantage over conservative therapy.
openaire   +2 more sources